206 related articles for article (PubMed ID: 30471067)
1. Neoadjuvant CAPOX and bevacizumab alone for locally advanced rectal cancer: long-term results from the N-SOG 03 trial.
Tomida A; Uehara K; Hiramatsu K; Maeda A; Sakamoto E; Okada Y; Kurumiya Y; Nakayama G; Nakamura M; Aiba T; Nagino M;
Int J Clin Oncol; 2019 Apr; 24(4):403-410. PubMed ID: 30471067
[TBL] [Abstract][Full Text] [Related]
2. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
[No Abstract] [Full Text] [Related]
3. Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial.
Uehara K; Hiramatsu K; Maeda A; Sakamoto E; Inoue M; Kobayashi S; Tojima Y; Yoshioka Y; Nakayama G; Yatsuya H; Ohmiya N; Goto H; Nagino M
Jpn J Clin Oncol; 2013 Oct; 43(10):964-71. PubMed ID: 23935207
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J;
Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study.
Yu X; Wang QX; Xiao WW; Chang H; Zeng ZF; Lu ZH; Wu XJ; Chen G; Pan ZZ; Wan DS; Ding PR; Gao YH
Cancer Commun (Lond); 2018 May; 38(1):24. PubMed ID: 29784042
[TBL] [Abstract][Full Text] [Related]
6. MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial.
Patel UB; Brown G; Machado I; Santos-Cores J; Pericay C; Ballesteros E; Salud A; Isabel-Gil M; Montagut C; Maurel J; Ramón-Ayuso J; Martin N; Estevan R; Fernandez-Martos C
Ann Oncol; 2017 Feb; 28(2):344-353. PubMed ID: 28426108
[TBL] [Abstract][Full Text] [Related]
7. Early results of multicenter phase II trial of perioperative oxaliplatin and capecitabine without radiotherapy for high-risk rectal cancer: CORONA I study.
Kamiya T; Uehara K; Nakayama G; Ishigure K; Kobayashi S; Hiramatsu K; Nakayama H; Yamashita K; Sakamoto E; Tojima Y; Kawai S; Kodera Y; Nagino M;
Eur J Surg Oncol; 2016 Jun; 42(6):829-35. PubMed ID: 26968228
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study.
Borg C; Mantion G; Boudghène F; Mornex F; Ghiringhelli F; Adenis A; Azria D; Balosso J; Ben Abdelghani M; Bachet JB; Vendrely V; François Y; Conroy T; Rio E; Roullet B; Spaëth D; Quero L; Lakkis Z; Coudert M; Ionescu-Goga M; Tanang A; André T
Clin Colorectal Cancer; 2019 Sep; 18(3):200-208.e1. PubMed ID: 31311761
[TBL] [Abstract][Full Text] [Related]
9. Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: Results of the BRANCH trial.
Avallone A; Pecori B; Bianco F; Aloj L; Tatangelo F; Romano C; Granata V; Marone P; Leone A; Botti G; Petrillo A; Caracò C; Iaffaioli VR; Muto P; Romano G; Comella P; Budillon A; Delrio P
Oncotarget; 2015 Oct; 6(30):30394-407. PubMed ID: 26320185
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of capecitabine plus oxaliplatin (CapOX) as adjuvant chemotherapy for locally advanced rectal cancer (CORONA II).
Hattori N; Nakayama G; Uehara K; Aiba T; Ishigure K; Sakamoto E; Tojima Y; Kanda M; Kobayashi D; Tanaka C; Yamada S; Koike M; Fujiwara M; Nagino M; Kodera Y
Int J Clin Oncol; 2020 Jan; 25(1):118-125. PubMed ID: 31542847
[TBL] [Abstract][Full Text] [Related]
11. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
Dewdney A; Cunningham D; Tabernero J; Capdevila J; Glimelius B; Cervantes A; Tait D; Brown G; Wotherspoon A; Gonzalez de Castro D; Chua YJ; Wong R; Barbachano Y; Oates J; Chau I
J Clin Oncol; 2012 May; 30(14):1620-7. PubMed ID: 22473163
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effects of oxaliplatin-based neoadjuvant chemotherapy and chemoradiotherapy in patients with locally advanced rectal cancer: a single-center, retrospective cohort study.
Okuyama T; Sameshima S; Takeshita E; Yoshioka R; Yamagata Y; Ono Y; Tagaya N; Noie T; Oya M
World J Surg Oncol; 2018 Jun; 16(1):105. PubMed ID: 29871650
[TBL] [Abstract][Full Text] [Related]
13. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.
Fernández-Martos C; Pericay C; Aparicio J; Salud A; Safont M; Massuti B; Vera R; Escudero P; Maurel J; Marcuello E; Mengual JL; Saigi E; Estevan R; Mira M; Polo S; Hernandez A; Gallen M; Arias F; Serra J; Alonso V
J Clin Oncol; 2010 Feb; 28(5):859-65. PubMed ID: 20065174
[TBL] [Abstract][Full Text] [Related]
14. PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer.
Sclafani F; Brown G; Cunningham D; Wotherspoon A; Tait D; Peckitt C; Evans J; Yu S; Sena Teixeira Mendes L; Tabernero J; Glimelius B; Cervantes A; Thomas J; Begum R; Oates J; Chau I
Ann Oncol; 2016 Aug; 27(8):1557-65. PubMed ID: 27217542
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of capecitabine plus oxaliplatin (CAPOX) as perioperative therapy for locally advanced rectal cancer.
Nishimura J; Hasegawa J; Kato T; Yoshioka S; Noura S; Kagawa Y; Yasui M; Ikenaga M; Murata K; Hata T; Matsuda C; Mizushima T; Yamamoto H; Doki Y; Mori M;
Cancer Chemother Pharmacol; 2018 Oct; 82(4):707-716. PubMed ID: 30078098
[TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
17. Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes.
Gollins S; Sun Myint A; Haylock B; Wise M; Saunders M; Neupane R; Essapen S; Samuel L; Dougal M; Lloyd A; Morris J; Topham C; Susnerwala S
J Clin Oncol; 2011 Mar; 29(8):1042-9. PubMed ID: 21263095
[TBL] [Abstract][Full Text] [Related]
18. Early response to upfront neoadjuvant chemotherapy (CAPOX) alone in low- and intermediate-risk rectal cancer: a single-arm phase II trial.
Deng X; Wu Q; Bi L; Yu Y; Huang S; He D; Wu B; Gou H; Meng W; Qiu M; He Y; Wang Z
Br J Surg; 2021 Dec; 109(1):121-128. PubMed ID: 34792107
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine and Oxaliplatin Prior and Concurrent to Preoperative Pelvic Radiotherapy in Patients With Locally Advanced Rectal Cancer: Long-Term Outcome.
Hess V; Winterhalder R; von Moos R; Widmer L; Stocker P; Jermann M; Herrmann R; Koeberle D
Clin Colorectal Cancer; 2017 Sep; 16(3):240-245. PubMed ID: 27687815
[TBL] [Abstract][Full Text] [Related]
20. Influence of concurrent capecitabine based chemoradiotherapy with bevacizumab on the survival rate, late toxicity and health-related quality of life in locally advanced rectal cancer: a prospective phase II CRAB trial.
Velenik V; Zadnik V; Omejc M; Grosek J; Tuta M
Radiol Oncol; 2020 Aug; 54(4):461-469. PubMed ID: 32738130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
